The case that Ozempic (NVO) and other GLP-1 medications could help people with substance use disorders is getting stronger.

The drugmaker's financial results are also impressive, spearheaded by tirzepatide, a therapy for diabetes and obesity that is ...

In that spirit, let's consider two biotech companies that could potentially deliver incredible returns next year: Recursion Pharmaceuticals (NASDAQ: RXRX) and BioAge Labs (NASDAQ: BIOA). Are these ...

Over the last couple of years, pharmaceutical giant Eli Lilly (NYSE: LLY) has made a splash in the red-hot weight loss space.

Weight-loss and diabetes drugs like Ozempic, Wegovy, Mounjaro or Zepbound appear to help people battle alcoholism an ...

The Center for Human Nutrition at the U of A is conducting a research study to learn more about the effects of protein on body composition and wellbeing in people getting ready to take weight loss ...

The U.S. Food and Drug Administration (FDA) is rethinking its decision to remove popular weight-loss and diabetes drugs from ...

In response to a lawsuit, the FDA has said that it will reevaluate its previous decision to remove tirzepatide from its ...

On October 7, a compounding trade group filed a lawsuit challenging the agency's action, saying there was still a shortage of ...

Eli Lilly's valuation could look much more modest in the future, as its earnings should continue to grow at a high rate.

Those include GLP-1s for obesity such as Novo Nordisk's Wegovy and Eli Lilly's Zepbound, which both carry hefty price tags of roughly $1,000 per month before insurance and other rebates.

“ (Weight loss medications) can help, for sure, but exercise and getting enough protein to make sure you aren’t losing muscle ...